A vasopressin V1A and V2 receptor antagonist (Kis = 0.48 and 3.04 nM for rat liver V1A and kidney V2, respectively); competitively inhibits oxytocin binding to rat uterine oxytocin receptors (Ki = 44 nM) but has no effect on AVP binding to anterior pituitary V1B receptors at concentrations up to 100 μM in a radioligand binding assay; suppresses AVP-induced increases in intracellular calcium in VSMCs and the pressor response in pithed rats; increases urine output and decreases urine osmolality in dehydrated conscious rats in a dose-dependent manner; reduces brain edema and blood-brain barrier disruption in a mouse experimental stroke model,